SEATTLE, Wash. and VANCOUVER, British Columbia, March 5, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its fourth quarter and year-end 2018 financial results on Thursday, March 14, 2019. Company management will host…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 22, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced final data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisinicline in smokers. Study results will be…
/Read More
Topline data from ORCA-1 trial expected in mid-2019 SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 20, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Dec. 18, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update. The U.S. Food and Drug Administration (FDA) has confirmed that they are in agreement with Achieve’s Initial…
/Read More
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, November 7, 2018 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical…
/Read More